Mendham Investment Group

Dr. Michael Ingber leads the firm's investment operations alongside co-founder and Managing Director Ido Zairi. Ingber is also a practicing urologist and director at Garden State Urology, which grounds the firm's investment process in clinical experience. Sol J. Barer, founder and former Celgene CEO, provides the strategic direction and scientific network that drive the group's deal-sourcing capability.

The firm deploys the personal capital of Sol J. Barer, who built his wealth over decades as CEO and later Chairman of Celgene. The biotechnology company's $74 billion acquisition by Bristol Myers Squibb in 2019 was a significant liquidity event. Mendham Investment Group does not raise outside funds or operate as a pooled investment vehicle.

Sourcing leans heavily on the principals' personal networks in biotechnology and clinical medicine. Sol Barer's standing in the life sciences community—he designed a leadership program for the Israeli 8400 Network of health-tech executives—opens doors to entrepreneurs and scientific founders. Dr. Ingber's urology practice provides a direct conduit to early-stage medical device companies and physician-driven innovations.

The group focuses on early-stage, pre-revenue life science companies, typically at the seed or angel stage. It invests directly rather than through institutional venture funds. Portfolio exposure spans therapeutics, diagnostics, and medical devices, with an emphasis on opportunities where the principals' scientific or clinical expertise can inform the investment thesis.

Yes. The group frequently partners with specialist co-investors who bring complementary expertise. A known co-investment partner is Rapha Capital Management, with whom Mendham has backed ventures such as FIZE Medical, a company developing fluid management technology. These syndicates typically involve direct equity rather than fund commitments.